Skip to main content
Silence Therapeutics plc logo

Silence Therapeutics plc — Investor Relations & Filings

Ticker · SLN ISIN · US82686Q1013 LEI · 213800SSURRJBX85SQ91 US Professional, scientific and technical activities
Filings indexed 627 across all filing types
Latest filing 2025-12-23 Director's Dealing
Country GB United Kingdom
Listing US SLN

About Silence Therapeutics plc

https://www.silence-therapeutics.com/

Silence Therapeutics plc is a clinical-stage biotechnology company pioneering the design and development of medicines based on short-interfering RNA (siRNA). The company utilizes its proprietary technology platform to create precision-engineered therapies that selectively silence the expression of disease-causing genes. Its clinical pipeline focuses on addressing conditions with high unmet medical needs in therapeutic areas such as cardiovascular disease, hematology, and rare diseases. Key product candidates in development include zerlasiran, targeting cardiovascular risk, and divesiran for polycythemia vera. The company aims to provide transformative treatments for patients who have limited or inadequate therapeutic options.

Recent filings

Filing Released Lang Actions
Director's Dealing 2025
Director's Dealing
2025-12-23 English
8-K/A
Regulatory Filings
2025-12-22 English
8-K
Regulatory Filings
2025-12-22 English
8-K
Regulatory Filings
2025-12-15 English
10-Q
Interim / Quarterly Report Q3 2025
2025-11-06 English
8-K
Regulatory Filings
2025-11-06 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.